Bemarituzumab

DB16105InvestigationalProtein Based Therapies

Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 2 and Low affinity immunoglobulin gamma Fc region receptor III-A
Curator reviewed
Also known as: Anti-fgfr2 monoclonal antibody fpa144
Code names: AMG 552 · FPA-144

Resolves to

Compound

UNIIRJW23BQ0KWCAS1952272-74-0

Targets

P21802FGFR2P08637FCGR3A

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

18Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Bemarituzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account